This article serves as a follow-up to my initial analysis in this article of Nuvation Bio ( NUVB ), where I outlined a bullish case for the oncology-focused biotech following the commercial launch of its first approved therapy, Ibtrozi—aI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operating my own boutique law f ...